
WALTHAM, Mass., Dec. 29 (UPI) -- U.S. firm Oscient Pharmaceuticals said Friday it has amended its Factive License Agreement with LG Life Sciences.
Specifically, the company said the amended license and option contract on Oscient's antibiotic Factive (gemifloxacin mesylate) tablets, adds several European countries to the license agreement, so that all of the current members of the European Union, or 40 member states, are included.
In another revision, Oscient said the contract's economic terms relating to Factive's European sales have been restructured to include a reduction in royalty rates on future sales "to enable maximum investment in the brand through a potential European partnership."
"One of Oscient's corporate development goals for Factive is identifying a partner for the commercialization of Factive in Europe; we are pleased that LG Life Sciences shares our vision for the product," Steven Rauscher, Oscient's president and CEO, said in a statement.
The company estimated the antibiotic market in Europe at $5 billion, with the four largest markets being France, Germany, Italy and Spain.
|
|
|
|
|
|
| Additional Health News Stories | |
MIAMI, May 27 (UPI) --
Tropical Storm Beryl neared hurricane strength ahead of its expected landfall Sunday night on the Southeast Coast of the United States, U.S. forecasters said.
|
'Men in Black' leads U.S. box office ... Michelle Obama, daughters see Beyonce ... Lady Gaga cancels Jakarta gig for security ... Madonna asks for pool at Israel venue ... News from United Press International.
|
ANCHORAGE, Alaska, May 27 (UPI) --
A black bear didn't go over a river but went to the woods after scampering through residential and industrial areas of Anchorage, Alaska, police said.
|
To avoid a meltdown in 2006, Ford Motor Co. mortgaged the farm putting up its assets – including its Blue Oval logo, and F-150 pickup and iconic Mustang trademarks – to secure $23.5 billion in credit.
|
| Stories | Photos | People | Comments |
View Caption